Drug profile · INN
tralokinumab
ADTRALZA
tralokinumab (ADTRALZA) is a interleukin-13 inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — tralokinumab
- US status
- approved
- Class
- Dermatologicals (D11)
- Route
- INJECTION
- Patents
- 0
- Programs
- 4
- Data quality
- 0.84
Quick answer
tralokinumab (ADTRALZA) is a interleukin-13 inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Interleukin-13 inhibitor
Primary target: Interleukin-13
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is tralokinumab?
tralokinumab (ADTRALZA) is a interleukin-13 inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for tralokinumab?
ADTRALZA is a marketed brand name for tralokinumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tralokinumab?
tralokinumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.